Schedule an Appointment

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
Book a Conference Call
Get More Information

IGY Life Sciences Inc.

 

Location: Thunder Bay, Ontario

Sector: Life Science

 

Add to Shortlist
Express Interest

IGY Life Sciences controls platform technology to extract and purify IgY (Immunoglobulin) from egg yolk, in kilogram quantities for $.0035 per mg. Comparable technology can either only produce milligram quantities at very high price ($50 plus per mg) or in large quantities at very low purity. The company produces Muno-IgY, a protein isolate from egg yolk also referred to as Immunoglobulin. It is sold as a nutraceutical to support the immune system, Muno-IgY is classified as a non-specific polyclonal antibody.

Business Documents

1.First to market with high purity IgY – Our extraction technology can purify IgY antibodies up to 90% pure by content. Our nearest competitor can only purify up to 2%.

2.Most cost Effective – For 90% pure IgY, the only available technology costs thousands of dollars per gram. We cost dollars per gram.

3.Fast-to-market pharmaceuticals – With 800 published research papers in the field, much of the heavy lifting has been completed.

4.Long shelf life – Excellent property for pandemic preparedness and bio-terrorism products that would sit on a shelf for years prior to use.

5.Builds the agriculture sector – Our technology will begin by using the surplus egg supply but will eventually move toward building a whole new supply chain using millions of egg laying birds.

IGY Life Sciences controls platform technology to extract and purify IgY (Immunoglobulin) from egg yolk, in kilogram quantities for $.0035 per mg. Comparable technology can either only produce milligram quantities at very high price ($50 plus per mg) or in large quantities at very low purity. The company produces Muno-IgY, a protein isolate from egg yolk also referred to as Immunoglobulin. It is sold as a nutraceutical to support the immune system, Muno-IgY is classified as a non-specific polyclonal antibody.

Terry N. Dyck, President & CEO
Mr. Dyck comes to IGY Life Sciences from the financial services markets industry where he was a President’s level Senior Investment Advisor for Wellington West Capital. With a background in science, Mr. Dyck saw an opportunity with the technology developed by IRI Separation and in 2009, when the company had a financial melt-down, he negotiated to purchase the assets and founded IGY Life Sciences. His focus at IGY Life Sciences is to get to a cash-flow positive position in the shortest period of time, and allow the company to build into an international pharmaceutical company with the least amount of risk to investors.
Nadia LaRussa, CFO
Nadia La Russa is a passionate Thunder Bay entrepreneur with various business interests, the primary one being in the field of accounting. Nadia has developed six companies in the past decade that continue to grow and be competitive in their markets. Through her exposure from founding and managing a private accounting firm, Nadia has gained over 15 years of experience with controllership, accounting, bookkeeping and income tax. A recent MBA graduate, Nadia will be expanding her expertise and role with IGY Immune Technologies & Life Sciences Inc as the Chief Financial Officer.
John Mason, C.A., B.Sc. Director of Research
Mr. Mason is a member of the British Columbia and Canadian Institute of Chartered Accountants and the Institute of Chartered Accountants of England & Wales. Mr. Mason holds a Bachelor of Science degree from the University of London. As a result of the merger of his accounting practice and his science background, he was asked to head up the construction of a commercial facility to utilize electron beam technology developed by Atomic Energy of Canada and establish commercial applications for this high energy radiation technology. He arranged the financing and oversaw the building of the Electron Beam facility in Port Coquitlam, British Columbia – he then worked with leading International organizations to secure their business for the facility.
In 2000 he was approached by the University of British Columbia to see if he could commercialize technology the University had developed for the extraction of Immunoglobulin Antibodies from Bovine Whey and Egg Yolk.
Jeff Stubbings, Operations Manager
Jeff Stubbings is a Senior Systems and Operations Manager, currently working full-time for the Province of Ontario. He is a results-driven leader with over 15 years-experience delivering successful projects on-time and on budget. Masterful in building teams, relationships, systems, operations and processes. Proven success in the design, development, implementation of award winning programs and products. An effective leader and coach of people and recognized as an agent of change.
Jit Mistry, Director of Marketing
Prior to joining the Company, Mr. Mistry was a founder and Chief Executive Officer of Alterra Capital Inc, a diversified financial services holding company specializing in alternative asset classes including private equity, real estate and hedge funds. He brings more than 16 years of experience in the financial services industry. Prior to Alterra, Mr. Mistry was co-founder of Pescara Partners Inc., a hedge fund of funds manager that was subsequently acquired by Jovian Capital Corporation in 2004. Mr. Mistry remained with Jovian subsidiary, responsible for strategic product development, branding and marketing initiatives for the firm’s investment offerings to retail investment advisors. Prior to Pescara Partners, Mr. Mistry co-founded a consultancy firm specializing in product development, distribution and business development services to the financial services industry. Mr. Mistry was also with major mutual fund company for 8 years in a senior role in sales and marketing.
Kevin Somerville, MSC., B.Sc. V.P Sales Muno-IgY
Mr. Somerville was the quality control Manager with Akrion Life Sciences from 1995-2003 and has the unique experience of understanding the science behind IgY, prior to become their leading sales member. He develop sales from $3.3M to over $36M in less than 24 months while at Akrion, all based on IgY products.